The estimated Net Worth of Michael W Bonney is at least $12.6 million dollars as of 27 December 2023. Mr. Bonney owns over 30,000 units of Alnylam Pharmaceuticals Inc stock worth over $12,055,455 and over the last 13 years he sold ALNY stock worth over $0. In addition, he makes $505,707 as Independent Chairman of the Board at Alnylam Pharmaceuticals Inc.
Michael has made over 26 trades of the Alnylam Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 30,000 units of ALNY stock worth $2,893,500 on 27 December 2023.
The largest trade he's ever made was buying 71,520 units of Alnylam Pharmaceuticals Inc stock on 28 February 2019 worth over $999,850. On average, Michael trades about 2,328 units every 60 days since 2012. As of 27 December 2023 he still owns at least 46,029 units of Alnylam Pharmaceuticals Inc stock.
You can see the complete history of Mr. Bonney stock trades at the bottom of the page.
Michael W. Bonney is Independent Chairman of the Board of the Alnylam Pharmaceuticals, Inc. Mr. Bonney has served as the Executive Chair of Kaleido Biosciences, a biotechnology company, since June 2017. From June 2017 until August 2018, he also served as Kaleido’s Chief Executive Officer. Mr. Bonney was a Partner at Third Rock Ventures, a healthcare venture firm, from January to July 2016. Mr. Bonney previously served as the Chief Executive Officer and a member of the board of directors of Cubist Pharmaceuticals, Inc., a biopharmaceutical company (now a wholly-owned subsidiary of Merck & Co., Inc.), from June 2003 until his retirement in December 2014. From January 2002 to June 2003, he served as Cubist’s President and Chief Operating Officer. In addition, Mr. Bonney is the Chair of the board of directors of Magenta Therapeutics, Inc. and serves as a director of Celgene Corporation, Syros Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc. Mr. Bonney formerly served as a director of Global Blood Therapeutics, Inc., NPS Pharmaceuticals, Inc. and Cubist.
As the Independent Chairman of the Board of Alnylam Pharmaceuticals Inc, the total compensation of Michael Bonney at Alnylam Pharmaceuticals Inc is $505,707. There are 12 executives at Alnylam Pharmaceuticals Inc getting paid more, with John Maraganore having the highest compensation of $7,317,860.
Michael Bonney is 61, he's been the Independent Chairman of the Board of Alnylam Pharmaceuticals Inc since 2016. There are 9 older and 11 younger executives at Alnylam Pharmaceuticals Inc. The oldest executive at Alnylam Pharmaceuticals Inc is Phillip Sharp, 75, who is the Independent Director.
Michael's mailing address filed with the SEC is 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142.
Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal et Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include: